Intrommune Therapeutics Launches #PeanutAllergyStrong
August 24, 2021 12:25 ET
|
Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
August 11, 2021 13:37 ET
|
Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Global Food Allergy and Intolerance Products Market Report 2021: Market to Reach $32 Billion by 2027 - Broad Availability of Products Encourage Market Growth
August 09, 2021 08:08 ET
|
Research and Markets
Dublin, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The "Food Allergy and Intolerance Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
July 28, 2021 14:10 ET
|
Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
July 22, 2021 16:57 ET
|
Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics to Present at BIO Digital 2021
June 17, 2021 09:11 ET
|
Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Zoom-In on Health Equity: AAFA Asks Congress to Tackle Racial Disparities in Asthma and Allergy
April 30, 2021 14:22 ET
|
Asthma and Allergy Foundation of America
Washington, D.C, April 30, 2021 (GLOBE NEWSWIRE) -- Each year, the Asthma and Allergy Foundation of America (AAFA) brings patient spokespeople and advocates from across the nation to Congress to...
AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
April 29, 2021 14:03 ET
|
Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
AAFA Celebrates Massive Health Policy Change; Lawmakers Pass FASTER Act Making Sesame A Major Food Allergen
April 14, 2021 17:55 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Today the House passed Act, S. 578/H.R.1202, otherwise known as the FASTER Act. It declares sesame the 9th major food allergen recognized by law...
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET
|
Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...